Drugs /

axillary lymph node dissection

Back to Drugs List

Overview

NCI Definition [1]:
Surgical removal of the lymph nodes located in the cavity beneath the junction of the arm and the thorax, or axilla (armpit). This procedure is commonly performed as a component of cancer staging.

Clinical Trials

View Clinical Trials for axillary lymph node dissection

Axillary lymph node dissection has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating axillary lymph node dissection, 1 is phase 3 (1 open).

HER2 Indeterminate Placeholder is the most frequent biomarker inclusion criterion for axillary lymph node dissection clinical trials.

Breast carcinoma is the most common disease being investigated in axillary lymph node dissection clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Axillary Lymph Node Dissection
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating axillary lymph node dissection and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
alnd, axillary dissection, axillary lymphadenectomy, axillary node dissection, excision axillary lymph nodes
NCIT ID [1]:
C15677

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.